primary erythermalgia

ORPHA: 900262 Treatments Available

Contents

1. Overview
2. Available Treatments
3. Clinical Presentation
4. Classification & Codes

Overview

erythermalgie

Available Treatments (2)

Drug	Form	Status	Countries	Lead Time
carbamazepine	oral tablet 200mg, 400mg; extended-release tablet; oral suspension 100mg/5mL	FDA Approved	11	7d
mexiletine Orphan	oral capsule 150mg, 200mg, 250mg	FDA Approved	5	14d

Clinical Presentation

Signs and symptoms associated with primary erythermalgia, sourced from HPO and Orphanet clinical annotations.

Peripheral neuropathyErythemaErythromelalgiaPruritusAbnormality of thrombocytesLeukemiaHypothermiaRecurrent respiratory infectionsVasculitisDistal sensory impairmentPedal edemaAllodyniaDysesthesiaDecreased/absent ankle reflexes

Classification & Codes

Orphanet Code

ORPHA:90026

primary erythermalgia

Orphanet	`ORPHA:90026`
Treatments	2 drug(s)
Symptoms on record	14 signs
Status	published

Treatment Summary

carbamazepine mexiletine· Orphan

Factual Authority

Last Updated3/20/2026

Clinical DataHPO · Orphanet

Drug DataFDA · EMA · CDSCO